The 4 analysts offering 12-month price forecasts for ADC Therapeutics SA have a median target of 48.50, with a high estimate of 55.00 and a low estimate of 37.00. The median estimate represents a +125.06% increase from the last price of 21.55.
The current consensus among 5 polled investment analysts is to Buy stock in ADC Therapeutics SA. This rating has held steady since June, when it was unchanged from a Buy rating.Move your mouse over past months for detail
Earnings and Sales Forecasts
Earnings per Share -$0.86
Reporting Date Aug 24
Earnings per Share
Move your mouse over a quarter or year to see how estimates have changed over time.